Cabozantinib-s-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma [clinicaltrials:NCT02243605]

Bio2RDF uri

Cabozantinib-s-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma [clinicaltrials:NCT02243605]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT02243605

Bio2RDF identifier

NCT02243605

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT02243605

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

This phase II trial stu ...... zymes needed for cell growth.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Cabozantinib-s-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Non-progression, defined as complete response, partial response, or stable disease (osteosarcoma) At 6 months [clinicaltrials_resource:52be8352192a4dc2d2907389e2ea8f69]

Non-progression, defined as complete response, partial response, or stable disease (osteosarcoma) At 6 months [clinicaltrials_resource:a677f6963fb51d78a59bf5d7c9290747]

Non-progression, defined as complete response, partial response, or stable disease (osteosarcoma) At 6 months [clinicaltrials_resource:ebab961ad7e18bb034b322e4ccf42558]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Non-progression, defined as complete response, partial response, or stable disease (osteosarcoma) At 6 months [clinicaltrials_resource:2d49d40f51adcb3bd99aac16f7a797a5]

Non-progression, defined as complete response, partial response, or stable disease (osteosarcoma) At 6 months [clinicaltrials_resource:36b3d7668fb651bd1e89240d5a7ae206]

Non-progression, defined as complete response, partial response, or stable disease (osteosarcoma) At 6 months [clinicaltrials_resource:9e24c16edd39e423bf2131b96bb8f79d]

Non-progression, defined as complete response, partial response, or stable disease (osteosarcoma) At 6 months [clinicaltrials_resource:9f5129705961b6912a55d6bee14fafac]

condition [clinicaltrials_vocabulary:condition]

Metastatic Osteosarcoma [clinicaltrials_resource:29dd17763b230e30459decebca23a32b]

Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor [clinicaltrials_resource:50a9a8b89d371d08388df48137a2f288]

Recurrent Osteosarcoma [clinicaltrials_resource:7de732f5e8a1c8f8aa531f199532b8b9]

Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor [clinicaltrials_resource:9b2b2083f89045288a76f9f845d857df]

condition browse [clinicaltrials_vocabulary:condition-browse]

Osteosarcoma [clinicaltrials_resource:0a383a28c29973c7eb9048a7bcf537d1]

Neuroectodermal Tumors [clinicaltrials_resource:21a430214e8ab0239618f03cb2ccbcd9]

Neuroectodermal Tumors, Primitive, Peripheral [clinicaltrials_resource:74f847a957cd1d76dbb0e02dc4a4e00c]

Sarcoma, Ewing [clinicaltrials_resource:c0106e40bbdd04c3dd8d274a2d6ebd03]

Sarcoma [clinicaltrials_resource:de44dc73df720684ee1b130e7c8d0af4]

Neuroectodermal Tumors, Primitive [clinicaltrials_resource:eb31c64d3a09418f3c4e98dc74975f21]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Osteosarcoma [clinicaltrials_resource:0a383a28c29973c7eb9048a7bcf537d1]

Neuroectodermal Tumors [clinicaltrials_resource:21a430214e8ab0239618f03cb2ccbcd9]

Neuroectodermal Tumors, Primitive, Peripheral [clinicaltrials_resource:74f847a957cd1d76dbb0e02dc4a4e00c]

Sarcoma, Ewing [clinicaltrials_resource:c0106e40bbdd04c3dd8d274a2d6ebd03]

Sarcoma [clinicaltrials_resource:de44dc73df720684ee1b130e7c8d0af4]

Neuroectodermal Tumors, Primitive [clinicaltrials_resource:eb31c64d3a09418f3c4e98dc74975f21]

country [clinicaltrials_vocabulary:country]

France [clinicaltrials_resource:0309a6c666a7a803fdb9db95de71cf01]

detailed description [clinicaltrials_vocabulary:detailed-description]

PRIMARY OBJECTIVES: ...... e followed up every 6 months.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT02243605 [clinicaltrials_resource:77f4c9d46c6293337a9c20545e3c5515]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2014-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Laboratory Biomarker Analysis [clinicaltrials_resource:ba4309f1efad38e1ae44127895c9df9a]

Cabozantinib S-malate [clinicaltrials_resource:c2f95bfd0a6fce0433d9e6681036bc68]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-07-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

National Cancer Institute (NCI) [clinicaltrials_resource:a5725923b7e37779ae6f8b04acb7f59c]

location [clinicaltrials_vocabulary:location]

Institut Bergonie Cancer Center [clinicaltrials_resource:74f1daeb7990e9083aaeb669d2dd1ff1]

nct id [clinicaltrials_vocabulary:nct-id]

NCT02243605

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Phase 2 Study of XL184 (Cabo ...... teosarcomas and Ewing Sarcomas

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

NCI-2014-01927

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Antoine Italiano [clinicaltrials_resource:02ba68e6f690b68e24aa069eb66dd697]

overall status [clinicaltrials_vocabulary:overall-status]

Recruiting [clinicaltrials_resource:5231dee7156b84b0d1854de1a18dd169]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:be4cea82cb21bbda79c939a4d720315b]

phase [clinicaltrials_vocabulary:phase]

Phase 2 [clinicaltrials_resource:56e0338b27a2d68f77402c88327b3f8d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

NCI-2014-01927

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

National Cancer Institute (NCI) [clinicaltrials_resource:a5725923b7e37779ae6f8b04acb7f59c]

start date [clinicaltrials_vocabulary:start-date]

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT02243605 study design [clinicaltrials_resource:34cc6511997855fd0926864d98294cd6]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT02243605

verification date [clinicaltrials_vocabulary:verification-date]

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT02243605

http://www.w3.org/2001/XMLSchema#string

title

Cabozantinib-s-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Cabozantinib-s-malate in Treat ...... a [clinicaltrials:NCT02243605]

@en